Bio-Techne Corp
$ 71.77
0.41%
16 Jul - close price
- Market Cap 11,182,531,000 USD
- Current Price $ 71.77
- High / Low $ 71.81 / 71.45
- Stock P/E 102.53
- Book Value 13.32
- EPS 0.70
- Next Earning Report 2026-08-05
- Dividend Per Share $0.32
- Dividend Yield 0.45 %
- Next Dividend Date -
- ROA 0.07 %
- ROE 0.05 %
- 52 Week High 71.93
- 52 Week Low 43.12
About
Bio-Techne Corporation develops, manufactures, and sells life science reagents, instruments, and services for the global clinical diagnostic and research markets. The company is headquartered in Minneapolis, Minnesota.
Analyst Target Price
$70.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-06 | 2026-02-04 | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-02-05 | 2024-10-30 | 2024-08-07 | 2024-05-01 | 2024-02-01 | 2023-10-31 | 2023-08-08 |
| Reported EPS | 0.53 | 0.46 | 0.36 | 0.53 | 0.56 | 0.42 | 0.42 | 0.49 | 0.48 | 0.4 | 0.41 | 0.55 |
| Estimated EPS | 0.53 | 0.43 | 0.36 | 0.5 | 0.51 | 0.39 | 0.38 | 0.49 | 0.46 | 0.41 | 0.44 | 0.55 |
| Surprise | 0 | 0.03 | 0 | 0.03 | 0.05 | 0.03 | 0.04 | 0 | 0.02 | -0.01 | -0.03 | 0 |
| Surprise Percentage | 0% | 6.9767% | 0% | 6% | 9.8039% | 7.6923% | 10.5263% | 0% | 4.3478% | -2.439% | -6.8182% | 0% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.46 |
| Currency | USD |
Previous Dividend Records
| May 2026 | Feb 2026 | Nov 2025 | Aug 2025 | May 2025 | Feb 2025 | Jan 1970 | Nov 2024 | Aug 2024 | May 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-05-29 | 2026-02-27 | 2025-11-28 | 2025-08-29 | 2025-05-30 | 2025-02-28 | None | 2024-11-22 | 2024-08-30 | 2024-05-24 |
| Amount | $0.08 | $0.08 | $0.08 | $0.08 | $0.08 | $0.08 | $0.08 | $0.08 | $0.08 | $0.08 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TECH
2026-07-17 12:08:48
This article summarizes Bio-Techne's (TECH) presentation at the Goldman Sachs 45th Annual Global Healthcare Conference. Key takeaways include 2% overall growth, with strong performance in Diagnostics and Genomics, and significant growth in cell and gene therapy. The company highlighted improving market trends, particularly in biopharma funding and the China market, and discussed product strength in spatial biology and liquid biopsy, despite instrument pressure.
2026-07-16 20:09:15
This article analyzes Bio-techne Corp (NASDAQ: TECH), noting neutral near-term readings and strong mid-term sentiment, with a breakout underway. It presents three AI-generated trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy. The analysis also includes multi-timeframe signal data, highlighting key support and resistance levels for various time horizons.
2026-07-15 17:40:10
Bio-Techne (TECH) presented at the Bank of America Global Healthcare Conference 2026, where they discussed their Q3 performance, showing a 2% decline due to order timing and weak early-stage biotech demand, yet core products and growth verticals like cell and gene therapy and spatial biology performed well. The company highlighted robust growth in China and an EBITDA margin of 34.2%. Despite current headwinds, Bio-Techne anticipates recovery in fiscal 2027, driven by biotech stabilization, increased funding, and alignment with AI and automation trends.
2026-07-15 16:40:30
Bio-Techne (TECH) announced a proxy filing summary detailing its acquisition by Merck KGaA, Darmstadt, Germany, expected to close by late 2026 or early 2027. The summary outlines the integration strategy, risks, and the need for shareholder approval. The filing also references prior information on the board of directors and corporate governance, with any changes in holdings to be disclosed in future SEC filings.
2026-07-15 16:09:52
This article analyzes the Q1 earnings performance of Bio-Techne (NASDAQ:TECH) and other companies in the research tools & consumables sector. Bio-Techne's revenues fell short of expectations, but the stock still rose. Waters Corporation (NYSE:WAT) and Avantor (NYSE:AVTR) showed strong performance, while Revvity (NYSE:RVTY) and Agilent (NYSE:A) had mixed results.
2026-07-15 14:43:23
Bio-Techne (TECH) presented a summary of its financial performance and market dynamics at the Stifel 2025 Healthcare Conference. The company reported a 1% organic revenue decline due to specific GMP protein customers, but showed underlying growth in academic, biotech, pharma, and China markets. Management expressed optimism for future quarters, anticipating stabilization in end markets and continued growth in key segments like pharma and the long-term GMP business.
